- Home
- MPW vs ARWR Comparison
MPW vs ARWR Comparison
Compare MPW & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- ARWR
- Stock Information
- Founded
- MPW 2003
- ARWR 2003
- Country
- MPW United States
- ARWR United States
- Employees
- MPW N/A
- ARWR N/A
- Industry
- MPW Real Estate Investment Trusts
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- ARWR Health Care
- Exchange
- MPW Nasdaq
- ARWR Nasdaq
- Market Cap
- MPW 2.4B
- ARWR 2.4B
- IPO Year
- MPW 2005
- ARWR 1993
- Fundamental
- Price
- MPW $4.33
- ARWR $19.76
- Analyst Decision
- MPW Hold
- ARWR Buy
- Analyst Count
- MPW 6
- ARWR 11
- Target Price
- MPW $4.92
- ARWR $43.33
- AVG Volume (30 Days)
- MPW 13.8M
- ARWR 1.5M
- Earning Date
- MPW 02-19-2025
- ARWR 02-04-2025
- Dividend Yield
- MPW 7.44%
- ARWR N/A
- EPS Growth
- MPW N/A
- ARWR N/A
- EPS
- MPW N/A
- ARWR N/A
- Revenue
- MPW $660,172,000.00
- ARWR $3,551,000.00
- Revenue This Year
- MPW N/A
- ARWR $3,402.96
- Revenue Next Year
- MPW N/A
- ARWR $123.96
- P/E Ratio
- MPW N/A
- ARWR N/A
- Revenue Growth
- MPW N/A
- ARWR N/A
- 52 Week Low
- MPW $3.08
- ARWR $17.05
- 52 Week High
- MPW $6.55
- ARWR $36.72
- Technical
- Relative Strength Index (RSI)
- MPW 61.22
- ARWR 49.29
- Support Level
- MPW $3.93
- ARWR $17.75
- Resistance Level
- MPW $4.23
- ARWR $19.19
- Average True Range (ATR)
- MPW 0.23
- ARWR 1.02
- MACD
- MPW 0.06
- ARWR 0.10
- Stochastic Oscillator
- MPW 91.11
- ARWR 66.34
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc is a healthcare facility REIT. The company operates one segment, which owns and leases healthcare facilities. The vast majority of Medical's revenue is generated in the United States, followed by Germany and the United Kingdom. It provides financing for a variety of facilities that require funds for acquisitions, sale-leasebacks, new developments, and expansion projects.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.